Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01980589 | A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects(CHAMPION 2) | completed | Phase 1 | 22 | AmgenINDUSTRY | 1 | May 30, 2017 | clinicaltrials |
| NCT00513474 | Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 46 | Massachusetts General HospitalOTHER | 1 | May 25, 2017 |
| clinicaltrials |
| NCT00601718 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01582295 | XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease | completed | Phase 1 | 4 | Massachusetts General HospitalOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01432600 | Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide | completed | Phase 1 / Phase 2 | 80 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT03057418 | Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim | completed | Phase 1 | 7 | Biointegrator LLCINDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT00150462 | Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | completed | Phase 1 | 48 | AmgenINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT01949532 | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease | completed | Phase 1 | 26 | AmgenINDUSTRY | 3 | May 2, 2017 | clinicaltrials |
| NCT02072863 | A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 9 | AmgenINDUSTRY | 3 | May 2, 2017 | clinicaltrials |
| NCT01471067 | Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | completed | Phase 1 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01226849 | Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma(SGH652) | completed | Phase 1 | 6 | Singapore General HospitalOTHER | 1 | Apr 27, 2017 | clinicaltrials |
| NCT00693602 | Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma | completed | Phase 1 | 87 | St. Jude Children's Research HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT00923910 | Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood | completed | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Apr 12, 2017 | clinicaltrials |
| NCT00446342 | Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies | completed | Phase 1 | 21 | Sunesis PharmaceuticalsINDUSTRY | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01004991 | Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma | completed | Phase 1 / Phase 2 | 14 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 10, 2017 | clinicaltrials |
| NCT01120834 | Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL) | completed | Phase 1 / Phase 2 | 17 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 10, 2017 | clinicaltrials |
| NCT01323751 | Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma(ACY-1215) | completed | Phase 1 / Phase 2 | 120 | CelgeneINDUSTRY | 1 | Apr 6, 2017 | clinicaltrials |
| NCT00005988 | Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy | completed | Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01000285 | EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma(ATLL) | completed | Phase 1 / Phase 2 | 18 | Washington University School of MedicineOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01900509 | Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 16 | St. Jude Children's Research HospitalOTHER | 1 | Mar 22, 2017 | clinicaltrials |
| NCT00733824 | Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma | completed | Phase 1 / Phase 2 | 61 | Washington University School of MedicineOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01831505 | Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents | completed | Phase 1 | 4 | Presage BiosciencesINDUSTRY | 1 | Feb 27, 2017 | clinicaltrials |
| NCT02401295 | ATRA, Celecoxib, and Itraconazole as Maintenance | completed | Phase 1 | 1 | University of IowaOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01019174 | Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma(MM_LEN_DEX_CY) | completed | Phase 1 / Phase 2 | 40 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00058617 | Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL | completed | Phase 1 | 13 | Baylor College of MedicineOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01475058 | CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | completed | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT01300026 | AMG 319 Lymphoid Malignancy FIH | completed | Phase 1 | 28 | AmgenINDUSTRY | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00201682 | Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 36 | John ByrdOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT00586690 | Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT | completed | Phase 1 | 47 | David Rizzieri, MDOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT00989586 | Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 35 | Beth ChristianOTHER | 1 | Feb 6, 2017 | clinicaltrials |
| NCT02598570 | Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma | completed | Phase 1 | 7 | AbbVieINDUSTRY | 1 | Feb 6, 2017 | clinicaltrials |
| NCT00633594 | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 39 | SCRI Development Innovations, LLCOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT01029054 | Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT01810120 | Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT | completed | Phase 1 / Phase 2 | 30 | Mariella EnocOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT00323323 | CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas | completed | Phase 1 | 24 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT02953808 | Phase 1 Study of GSK2315698 in Healthy Japanese Subjects | completed | Phase 1 | 18 | GlaxoSmithKlineINDUSTRY | 1 | Jan 19, 2017 | clinicaltrials |
| NCT02697552 | Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma | completed | Phase 1 | 13 | HUYABIO International, LLC.INDUSTRY | 1 | Jan 12, 2017 | clinicaltrials |
| NCT00477035 | Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies | completed | Phase 1 | 22 | Sally AraiOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT00741403 | A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies | completed | Phase 1 | 39 | Cornerstone PharmaceuticalsINDUSTRY | 2 | Dec 29, 2016 | clinicaltrials |
| NCT00334438 | Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 23, 2016 | clinicaltrials |
| NCT00104975 | Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 1 | 20 | Yale UniversityOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT00091624 | A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) | completed | Phase 1 | 77 | Celgene CorporationINDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT00825149 | A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma(GAUDI) | completed | Phase 1 | 137 | Hoffmann-La RocheINDUSTRY | 6 | Nov 4, 2016 | clinicaltrials |
| NCT00854126 | A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 38 | Genentech, Inc.INDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT00854152 | A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 121 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT00930514 | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma | completed | Phase 1 | 281 | Hoffmann-La RocheINDUSTRY | 22 | Nov 2, 2016 | clinicaltrials |
| NCT01122875 | A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma | completed | Phase 1 | 14 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
Data updated 23 days agoSource updated May 30, 2017source: clinicaltrials